CCDC91 Knockout MES-OV Polyclonal Cells are a CRISPR/Cas9-mediated gene disruption model targeting the CCDC91 gene in the MES-OV ovarian cancer cell line. This product consists of a heterogeneous polyclonal knockout population, providing a robust loss-of-function system that minimizes clonal bias and is suitable for functional genomics studies. The polyclonal format avoids artifacts associated with single-cell cloning and offers a representative knockout phenotype for downstream analysis.
The MES-OV cell line originates from a patient with mesenchymal subtype high-grade serous ovarian cancer (HGSOC), an aggressive malignancy with poor prognosis. This subtype is distinguished by invasive behavior and resistance to standard chemotherapy, and MES-OV cells retain typical mesenchymal features in culture, making them a clinically relevant model for studying the molecular drivers of HGSOC progression and drug response.
CCDC91 encodes an adaptor protein that facilitates the retrograde transport of mannose-6-phosphate receptors (M6PRs) from endosomes to the trans-Golgi network (TGN) via a clathrin/AP-1-dependent mechanism. It directly interacts with the AP-1 complex, clathrin, and M6PRs, and functions in concert with the retromer complex. By ensuring proper M6PR recycling, CCDC91 is critical for the delivery of lysosomal hydrolases. CRISPR/Cas9-mediated disruption of CCDC91 abolishes this retrograde pathway, causing M6PR mislocalization, aberrant secretion of lysosomal enzymes, and potential lysosomal dysfunction, which can also perturb Golgi architecture.
In mesenchymal subtype HGSOC cells, dysregulated endosomal trafficking and lysosomal biology have been implicated in tumor progression and drug resistance. The MES-OV knockout model enables investigation into how loss of CCDC91-mediated sorting affects ovarian cancer cell behavior. Mislocalized lysosomal enzymes may degrade extracellular matrix components, aiding invasion, while defective lysosomal function can alter autophagy and sensitize cells to specific therapies. Thus, this polyclonal knockout cell population is a relevant tool for studying the intersection of vesicular transport and cancer cell fitness in a clinically aggressive context.
These cells support diverse experimental applications, from basic cell biology to translational oncology. Researchers can validate CCDC91 knockout by Western blot and RT-qPCR, visualize M6PR distribution and Golgi morphology by immunofluorescence, and assess protein interactions via co-immunoprecipitation. Functional consequences can be measured using lysosomal enzyme activity assays, cell proliferation and migration tests, and drug sensitivity profiling. The polyclonal pool is also amenable to high-throughput screening for modifiers of lysosomal dysfunction, making it a valuable asset for target validation and drug discovery in ovarian cancer. For technical specifications and ordering, contact Ascent Research.
